Edition:
United Kingdom

Revance Therapeutics Inc (RVNC.OQ)

RVNC.OQ on NASDAQ Stock Exchange Global Market

25.30USD
24 Sep 2018
Change (% chg)

$0.20 (+0.80%)
Prev Close
$25.10
Open
$25.10
Day's High
$25.65
Day's Low
$25.10
Volume
25,233
Avg. Vol
72,188
52-wk High
$37.45
52-wk Low
$22.25

Chart for

About

Revance Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug... (more)

Overall

Beta: 1.63
Market Cap(Mil.): $842.90
Shares Outstanding(Mil.): 30.82
Dividend: --
Yield (%): --

Financials

  RVNC.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -3.43 -- --
ROI: -50.65 1.79 14.61
ROE: -52.67 3.28 16.33

Allergan says revenue from aesthetics unit may double by 2025

NEW YORK Allergan Plc said revenue from its medical aesthetics business could double by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox.

14 Sep 2018

CORRECTED-UPDATE 1-Allergan says revenue from aesthetics unit may double by 2025

NEW YORK, Sept 14 Allergan Plc said revenue from its medical aesthetics business could double by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox.

14 Sep 2018

BRIEF-Revance Reports Qtrly Loss Per Share $0.97

* REITERATES ITS FINANCIAL GUIDANCE PROVIDED IN JANUARY 2018 Source text for Eikon: Further company coverage:

08 May 2018

Earnings vs. Estimates